The U.S. Food and Drug Administration approved Genentech’s Actemra (tocilizumab) for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
https://www.pharmalive.com/wp-content/uploads/2021/03/FDA-Approves-First-Biologic-for-Rare-Debilitating-Lung-Disease-BioSpace-3-5-21.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2021-03-05 12:09:192021-03-05 12:09:19FDA Approves First Biologic for SSc-ILD